Concord Biotech Limited vs Narayana Hrudayalaya Ltd.
Last updated: 23 October 2026
Concord Biotech vs Narayana Hrudayalaya: A Healthcare Sector Showdown
In the dynamic Indian healthcare sector, two prominent players, Concord Biotech Limited and Narayana Hrudayalaya Ltd., represent different facets of the industry. Concord Biotech is a leading biopharmaceutical company specializing in fermentation-based APIs and formulations, while Narayana Hrudayalaya is a well-established chain of multi-specialty hospitals and heart centers. This comparison aims to provide MoneyDock readers with a data-driven analysis of their current market positions, helping investors make informed decisions. Both companies operate in essential healthcare segments, offering critical services and products, making their financial health and market performance of keen interest to investors looking at the long-term growth potential of India's healthcare landscape.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Narayana Hrudayalaya Ltd. |
|---|---|---|
| Current Price | ₹1270.70 | ₹1693.20 |
| 52-Week High | ₹1579.40 | ₹2080.30 |
| 52-Week Low | ₹1014.80 | ₹1605.30 |
| 1-Year Return | -7.88% | -10.55% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: Without specific Trailing P/E and Market Cap data for both companies, a direct comparison on valuation metrics is limited. Both show 'N/A' for these key indicators, which suggests that investors need to look at other fundamental factors, perhaps from their latest financial reports, to gauge their intrinsic value. However, based solely on current price, Narayana Hrudayalaya trades at a higher absolute price point than Concord Biotech. It's important to consider the underlying value and growth prospects rather than just the share price.
Returns: In terms of 1-Year Returns, neither company has delivered positive returns to shareholders, indicating a challenging period for the broader healthcare sector or specific company-related factors. Concord Biotech has a 1-Year Return of -7.88%, which, while negative, is marginally better than Narayana Hrudayalaya's -10.55%. This suggests that Concord Biotech has been relatively more resilient or less impacted by market headwinds over the past year compared to its peer.
Stability: To assess stability, we can look at the proximity of their current prices to their 52-week lows. Concord Biotech's current price of ₹1270.70 is significantly above its 52-week low of ₹1014.80, suggesting it has recovered somewhat from its lowest point or maintained a distance. Narayana Hrudayalaya, with a current price of ₹1693.20, is also above its 52-week low of ₹1605.30, but the difference is narrower. This closer proximity to its 52-week low for Narayana Hrudayalaya might suggest a slightly higher recent volatility or a more sustained downward pressure compared to Concord Biotech, indicating relatively less short-term price stability.
MoneyDock Verdict
Aggressive Investors: Given the negative 1-year returns for both, aggressive investors might view Concord Biotech as having slightly better relative performance (-7.88% vs -10.55%). Its current price also shows more distance from its 52-week low. However, with N/A for P/E and Market Cap, this is a speculative play requiring deeper fundamental analysis beyond these metrics.
Conservative Investors: For conservative investors, the lack of P/E and Market Cap data makes both stocks difficult to assess for traditional value. Both have experienced negative returns, indicating a period of weakness. Narayana Hrudayalaya's narrower gap between current price and 52-week low might suggest slightly higher recent risk, making both less appealing without more comprehensive financial details.
Long-Term SIP Investors: For long-term SIP investors, both companies operate in growth sectors of the Indian economy. While both have seen recent dips, providing potential entry points, the lack of valuation metrics makes it hard to say if they are currently undervalued. Concord Biotech's better relative 1-year return and position further from its 52-week low might give it a slight edge in terms of recent price action, but a diversified approach considering both companies' long-term business prospects would be prudent after further research into their financial health and future outlook.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.